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Abstract
A nuclear factor-κB (NF-κB) luciferase assay has been employed to identify the bengamides,
previously known for their anti-tumor activity, as a new class of immune modulators. A unique
element of this study was that the bengamide analogs were isolated from two disparate sources,
Myxococcus virescens (bacterium) and Jaspis coriacea (sponge). Comparative LC-MS/ELSD and
NMR analysis facilitated the isolation of M. viriscens derived samples of bengamide E (8) and
two congeners, bengamide E’ (13) and F’ (14) each isolated as an insperable mixture of
diastereomers. Additional compounds drawn from the UC Santa Cruz repository allowed
expansion of the structure activity relationship (SAR) studies. The activity patterns observed for
bengamide A (6), B (7), E (8), F (9), LAF 389 (12) and 13–14 gave rise to the following
observations and conclusions. Compounds 6 and 7 display potent inhibition of NF-κB (at 80 and
90 nM respectively) without cytotoxicity to RAW264.7 macrophage immune cells. Western blot
and qPCR analysis indicated that 6 and 7 reduce the phosphorylation of IκBα and the LPS-
induced expression of the pro-inflammatory cytokines/chemokines TNFα, IL-6 and MCP-1 but do
not effect NO production or the expression of iNOS. These results suggest that the bengamides
may serve as therapeutic leads for the treatment of diseases involving inflammation, that their anti-
tumor activity can in part be attributed to their ability to serve as immune modulating agents, and
that their therapeutic potential against cancer merits further consideration.
*To whom correspondence should be addressed. Tel: (831) 459-2603. pcrews@ucsc.edu.
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We believe that the side-by-side exploration of sponges and myxobacteria for bioactive
secondary metabolites can be rewarding. Marine sponges are now recognized as a superb
source of physiologically active compounds possessing immense structural diversity.1
Likewise, some myxobacteria also elaborate heteroatom-rich bioactive secondary
metabolites,2 including some that have been the seeds for developing clinically useful
therapeutics.3 The success, from 1970–2010, by Höfle and Reichenbach at HZI (formerly
the GBF) in isolating chemically prolific strains from this group has been captivating.2 Of
special interest to us are examples, though few in number, of myxobacterial secondary
metabolites possessing nearly identical molecular structures and biological functions
compared to those of sponge-derived products. Shown in Figure 1 are two such parallelisms
which intimate the possibility of congruent biosynthetic machinery operating in these very
different biota. The F-actin stabilizers,4 jasplakinolide5 (a.k.a. jaspamide6) (1), from a Jaspis
splendens sponge,7 versus chondramide D4, 8–10 (2), from the myxobacterium,
Chondromyces crocatus11 illustrate parallel biogenesis that involves halogenation, fusion of
a tetraketide to a tripeptide, and macrocyclization. As another similar example, there is just
one biogenesis difference, consisting of the presence or absence of the heteroatom ring,
between the Vacuolar ATPase inhibitors12 salicylihalamide (3) from a Haliclona sponge
genus13 compared to apicularen A (4), from the myxobacterial genus Chondromyces.14
Even though few salt-obligate marine myxobacteria have been isolated,15–18 the origin of
shared biosynthetic machinery for the pairs of natural products summarized above remains a
fascinating mystery. This stimulated our quest to probe the chemical biology of marine
sponges and terrestrial myxobacteria that appear to share identical biosynthetic machinery.
A serendipitous opportunity, which involved interfacing this interest with the goals of an
International Cooperative Biodiversity Group (ICBG) project to investigate natural products
with immune modulating activity,19 resulted in the accumulation of promising data. The
evaluation of 128 myxobacterial extracts in a nuclear factor kappa B (NF-κB) luciferase
assay20 provided the motivation to further explore the bioactive constituents of selected
strains. Dysregulation of the NF-κB protein complex is pathogenic in a wide variety of
diseases including AIDS,21 Alzheimers disease,22 artherosclerosis,23 arthritis24 and
cancer.25, 26 Since NF-κB has been implicated in many diseases it is now considered to be
an important therapeutic target for drug discovery.27
The five proteins in the mammalian NF-κB family are divided into two classes and in the
last decade intensive efforts have gone into the discovery of small molecule inhibitors.
These transcription regulating proteins, two denoted as NF-κB’s and three referred to as
Rel’s, are held in the cytoplasm in an inactive state by an inhibitory subunit called IκB
(inhibitory protein of the nuclear factor κB).28 Phosphorylation of IκB and its subsequent
degradation allows for translocation of NF-κB to the nucleus. Further, NF-κB activation in
cells is stimulated by pro-inflammatory agents such as bacterial endotoxins (e.g.
lipopolysacharide, LPS), cytokines, chemokines, carcinogens or oxidative stress. The
substantial efforts to explore NF-κB inhibitors includes 125 compounds reported in 199929
to the nearly 1000 to date, collectively summarized by the Gilmore lab.30 A vast majority
are natural products of plant biosynthetic origins,31 but very few exhibit low nM inhibition
of NF-κB signaling.30 One noteworthy exception is celastrol (5),32 which is being pursued
as an important anti-arthritic and anti-cancer therapeutic lead based on its impressive
activity in vivo.33, 34
A dichloromethane extract from a myxobacterium, Myxococcus virescens coded DSM
15898 FD, screened in the NF-κB luciferase assay during our ICBG collaboration, exhibited
anti-inflammatory effects comparable to celastrol (5) with no cytotoxicity to macrophage
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(RAW 264.7) immune cells (see Figure S1, Supporting Information). Secondary metabolites
of this M. virescens strain have been reported only in the patent literature and include
bengamide E (8) and other analogs.35 These preliminary results provided the justification to
launch a campaign, conducted in three phases, to examine the basis for the NF-κB luciferase
assay result. These actions involved: 1) identifying the metabolites in the extract responsible
for the anti-inflammatory activity, 2) side-by-side comparison of the myxobacterial
bengamides to analogs purified from the Indo Pacific sponge Jaspis coriacea, 36–39 and 3)
mechanistic investigation of the signal transduction pathways targeted by the active
compounds effecting NF-κB signaling. Herein, we report on the absolute configurations of
the myxobacterial derived bengamides. We also show that the bengamides exhibit nM
inhibition of NF-κB in RAW 264.7 cells and that this effect is associated with the inhibition
of phosphorylation of IκBα, and the reduced expression of the pro-inflammatory cytokines/
chemokines tumor necrosis factorα, (TNFα), interleukin-6 (IL-6) and monocyte
chemotactic protein-1, (MCP-1).
Results and Discussion
To rapidly pinpoint the metabolites responsible for the observed activity of the M. virescens
extract coded DSM 1598FD in the NF-κB luciferase assay20 we began by using the
previously reported LC-MS/ELSD based peak-library approach.19 Shown in Figure 2 are the
overlaying of peaks visualized by LC-MS/ELSD with data obtained from the NF-κB
luciferase assay. Several fractions displayed potency greater than the standard celastrol (5,
250 nM) (Figure 2) and include: H17 (341 m/z), H18 (245 m/z ) H19 (355 m/z), H20 (369
m/z), and H36 (416 m/z) The components exhibited m/z ions [M-H2O+H]+ that
corresponded to bengamide E (8, 341 m/z)38 F (9, 355 m/z),38 a simple diketopiperazine
(cyclo-Pro-Phe, 245 m/z, [M+H]+), and a unique m/z = 369 and 416. Scale up, reverse phase
HPLC of the parent dichloromethane (375.4 mg) and methanol (191.2 mg) extracts was
needed to provide more of the minor metabolites, especially the 341 m/z and of 369 m/z
components for further structural and bioassay analysis. Eventually semi-pure fractions of
these metabolites were obtained (see Scheme S1, supporting information). Fraction H36
exhibited chemical shifts and a m/z ion = 416 unrelated to the bengamide class and is
currently under investigation.
The process of correlating the myxobacterial metabolites with those of sponge-derived
counterparts warrants elaboration. The 341 m/z metabolite displayed an LC-MS retention
time parallel to the sponge-derived compound bengamide E (8), as shown Figure S2. Final
dereplication of this compound was based on the molecular formula of C17H30N2O6
established from HRESITOFMS m/z 381.2010 [M+Na]+, and 1H NMR spectrum of this
sample (Figure S3) which showed minor impurities alongside diagnostic δH values that
exactly matched those of bengamide E (8).38 Our analysis clearly indicated that the
terrestrial myxobacterium and marine sponge produced identical compounds.
The fraction coded as H19 (355 m/z) was a major metabolite, eventually concluded to be
bengamide E’ (13), which shared an LC-MS retention time equivalent to that of sponge-
derived bengamide F (9) (see in Figure S4). However, it quickly became evident that this
compound was a homologue of 8. The ESI-TOF-HRMS formula of C18H33N2O6, for
fraction H19, while identical to that of 9 exhibited NMR resonances that were markedly
different (see Figures S5). After repeated injections using either an analytical 5 μ reverse
phase or chiral HPLC column we concluded that this fraction contained an inseparable
mixture of diastereomers at position C-2 (ratio of 60:40, see Figure S19). Further inspection
of the 1D and 2D NMR data (shown in Table S1 and Figures S6–S10) indicated these
diastereomers, relative to bengamide E (8), were chain extended by an extra carbon on the
left end and are named here as bengamide E’(13). Most of the 1H NMR resonances at this
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terminal end were doubled (Figure S19) including those of the C2H5 group labeled R4
(Table 1), the CH3-15, and the vinyl group, H-4, and H-5. In comparison to bengamide E
(8), of absolute configuration 5R, 6S, 7R, 8R, and 10S, the new analogue is assigned to have
the same features. However, the terminal end methylation appears to have been
biosynthetically introduced in a scalemic fashion, which is consistent with multiple
resonances for the residues in the vicinity of this additional methyl. Analysis of
literature 13C NMR shifts provides a diagnostic pattern, shown in Figure 3, to further
address the configurations at these centers noted above. The comparison of Panel A plots
differences in 13C shifts of natural bengamide E (8) from J. coriacea36 versus data published
for 8 from three different enantiospecific total syntheses;40–42 and documents that the
variation in shifts at each site is < 1ppm. By contrast, the information of Panel B shows that
modification of the absolute configurations at C-6 and C-7 in the synthetic 8 diastereomer of
5R, 6R, 7S, 8R configuration, also obtained by an enantiospecific total synthesis,43 imparts a
>1 ppm change in the 13C NMR chemical shifts at the 3/4 sites. Finally, Panel C illustrates
the close parallelisms in shifts of the following set: (a) natural bengamide E (8), synthetic
bengamide E (8), (c) natural bengamide E’(13) as a diastereomeric mixture, and (d)
synthetic E’ (13) reported from a scalemic total synthesis.41
The active metabolite in fraction H20 (369 m/z) displayed properties similar to those of 13.
Its formula, C19H34N2O6, established by HRMS alongside the 1H NMR spectrum indicated
this was the N-methyl homologue of 13. It was named bengamide F’ (14), also isolated as a
mixture of diastereomers epimeric at position C-2. The configurations assigned of 14 were
based on a biosynthetic analogy to the co-occuring metabolite 8 with absolute configurations
5R, 6S, 7R, 8R, and 10S.
The preliminary assay data of Figure 2 showed a large inhibition in the initial NF-κB screen
of the LC-MS/ELSD fractions H17, H19, and H20 containing the compounds discussed
above. This provided the motivation to more fully assess the quality of these biological
responses. Also important was that the cytotoxicity data obtained against macrophage
immune (RAW 264.7) cells for these same fractions (see Supporting Information Figure S1)
indicated selectivity. Next, these two screens were repeated on purified compounds to
determine IC50 values. This evaluation was conducted on the following compounds: (a)
assay standard, celastrol (5); (b) the myxo-derived bengamides E (8), E’ (13), F’ (14); (c)
the sponge derived compounds obtained from our repository of bengamide A (6), B (7), E
(8), F (9); and (d) a synthetic bengamide analog, LAF-389 (12),44 previously evaluated by
Novartis in a Phase I clinical trial for the treatment of advanced cancer.45 Data was also
collected to assess the IC50 inhibition of cultured human colon tumor (HCT-116) cell lines
by this compound collection as shown in Table 1. All compounds exhibited significant NF-
κB inhibition as shown by the IC50 values (in parentheses) versus their toxicity assessment
against RAW 264.7 cells (≥ 50 μM). The two most active analogs consisted of 6 (0.08 μM)
and 7 (0.09 μM), which displayed low nanomolar activity compared to celastrol (5, 0.2
μM). Compounds 8–9 and 12–14 (7.5, 0.7, 0.5, 2.0, 2.0 μM) were less NF-κB inhibitory
suggesting a significant role of the myristate moiety in enhancing the potency of the NF-κB
inhibition. A similar trend was also observed for the presence and absence of the myristate
and its impact on the IC50 potencies of these various bengamide compounds against the
HCT-116 cell lines.
An extensive investigation using a proteomics approach has identified that 12 targets both
isoforms of human methionine aminopeptidase (MetAps 1 and 2) proteins.46 Further
investigations have shown that inhibition of MetAps by 6 led to the regulation of c-Src non-
receptor tyrosine kinase activity.47 More recently, the bengamide class has shown promise
for the treatment of tuberculosis as lead compounds based on this scaffold have the potential
to selectively inhibit M. tuberculosis MetAps vs human MetAps. Although inhibition of
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MetAps is one mechanism responsible for the antitumor activity of the bengamides, such a
mechanism may not account for their anti-inflammatory properties.49 However, the anti-
inflammatory properties of the bengamides are probably, or at least partially, also
responsible for their antitumor activities due to the close link between tumorigenesis and
inflammation.50, 51 Ongoing studies into the molecular targets of the bengamides
responsible for their biological activity affecting cancer and other diseases indicated that
further exploration of the role(s) they may play in the immune pathway could be useful.
Thus, the next step was to more thoroughly investigate the effects of the bengamides on the
signaling pathways that target NF-κB.
The NF-κB inhibitory activity of the bengamides A (6), B (7), E (8) and F (9) were
evaluated by Western Blot analysis shown in Figure 4, analyzing the degree of inhibition of
phosphorylation of IκBα, a common indicator of NF-κB inhibition.28, 52 With increasing
concentrations of 6 - 9, there is a clear decrease in the levels of observed IκBα
phosphorylation. Also shown by these data is that bengamide A (6) and B (7) are more
effective than E (8) and F (9). These Western immunoblot results, in combination with the
NF-κB luciferase assay, establish that the bengamide pharmacophore inhibits NF-κB
activation. Next the inhibitory effects of 6 and 7 on LPS stimulated nitric oxide (NO)
production and the pro-inflammatory cytokines/chemokines: inducible nitric oxide synthase
(iNOS), TNFα, IL-6 and MCP-1 were evaluated and these results are shown in Figure 5.
Neither 6 nor 7 showed NO inhibition activity or an effect on iNOS expression (data not
shown) at concentrations up to of 10 μM. Alternatively both compounds displayed
significant inhibition in a dose dependent manner against TNFα (6, IC50 ~ 0.5 μM; 7, IC50
~ 0.5 μM), IL-6 (6, IC50 ~ 1.0 μM; 7, IC50 ~ 0.5) and MCP-1 (6, IC50 ~ 0.5 μM; 7, IC50 ~
0.5 μM). The expression of TNFα,53, 54 IL-6,55, 56 and MCP-157, 58 are all closely linked to
diseases involving inflammation and cancer. The above results should now be considered
alongside additional findings that both the full bengamide structure46 as well as modified
synthetic bengamide analogs modulate methionine aminopeptidases.59 Overall we believe
that the bengamides affect key targets in the immune pathway and perhaps others that are
also responsible for their anti-tumor activity.
Conclusions
Several noteworthy conclusions can be drawn from our investigation of biologically active
myxobacteria derived extracts. The first is that bengamide E (8) and analogs E’ (13) and F’
(14) are in fact produced by M. virescens. With the exception of makaluvamine A, (isolated
from the sponge Zyzzya fuliginosa60 and myxomycetes “slime mold” Didymium
bahiense61) to the best of our knowledge this is only the second example in the peer-
reviewed literature of a sponge derived natural product reported from a cultured microbial
source. This is intriguing in that, of the thousands of compounds isolated from sponges, a
vast majority are presumed to owe their biosynthetic origins to the sponges microbial
symbionts62 but few examples exist. Furthermore, this finding underscores the potential
future discoveries that can come from the investigation of myxobacterial cultures.2 A second
important discovery is that the bengamides behave as immune modulating agents with
respect to their inhibition of NF-κB without accompanying cytotoxicity to RAW 264.7
immune cells. Structure activity relationship studies revealed that bengamide A (6) and B
(7) are the most potent at 80–90 nM, respectively. This class may therefore be able to serve
as therapeutic leads for immune disorders involving inflammation as they possess activity
on par with some of the most potent NF-κB inhibitors. Subsequent qPCR analysis indicated
that the bengamides modulate the expression of the pro-inflammatory cytokines,
TNFα,53, 54 IL-6,55, 56 and MCP-157, 58 and that their effects on these targets might also
contribute to their significant anti-tumor activity. Additional studies into the effects of
bengamides involving the NF-κB pathway may uncover new targets for this class to serve as
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molecular probes whereas they currently provide a unique scaffold to develop a novel class
of MetAP inhibitors for anti-bacterial, anti-tubercular and anti-cancer therapeutics.46, 48, 59
In summary, we have identified the bengamides as potent immune modulating agents from
the investigation of an extract of M. virescens. Our results suggest that further exploration
into myxobacterial derived secondary metabolite chemistry is warranted and has the
potential to uncover new interesting molecular structures that can be provided in a
sustainable fashion through fermentation and go on to serve as important therapeutic leads
for the treatment of a wide variety of human diseases.
Experimental Section
General Experimental Procedures
Analytical LC-MS analysis was performed on samples at a concentration of approximately 5
mg/mL, using a reversed-phase 150 × 4.60 mm 5 μm C18 Phenomenex Luna column in
conjunction with a 4.0 × 3.0 mm C18 (Octadecyl) guard column and cartridge (Holder part
number: KJ0-4282, Cartridge part number: AJ0-4287, (Phenomenex, Inc., Torrance, CA).
Samples were injected onto the column using a volume of 15 μL, with a flow rate of 1 mL/
min that was monitored using a Waters model 996 photodiode array (PDA) UV detector.
The elution was subsequently split (1:1) between a S.E.D.E.R.E. model 55 evaporative light
scattering detector (ELSD), and an Applied Biosystems Mariner electrospray ionization time
of flight (ESI-TOF) mass spectrometer. All NMR experiments were run on a Varian INOVA
600 spectrometer (600 and 150 MHz for 1H and 13C, respectively).
Biological Material, Collection and Identification
Specimens of the myxobacteria strain DSM 15898 were obtained from the Deutsche
Sammlung von Mikroorganismen und Zellkulturen (German Collection of Microorganims
and Cell Cultures) taxonomically identified as M. virescens as reported previously.35
Pure Compounds
Celastrol (5) was obtained from Cayman Chemical Company, Ann Arbor, MI, USA.
Bengamide A, B, E, and F (6–9), were obtained from the UCSC marine natural products
repository from specimens of J. coriacea using methods reported previously.36 Additional
amounts of bengamide A (6) and (7) were supplied by C-GRO Biosciences LLC, Santa
Cruz, CA, USA. LAF-389 (12) was provided by Novartis Institutes for Biomedical Research
(NIBR).
Extraction and Prefractionation
We obtained DSM15898 from the Deutsche Sammlung von Mikroorganismen und
Zellkulturen. It arrived as freeze-dried cells which were taken up in a minimum amount of
sterile water and spread onto VY2 agar plates (pH = 7.2). Bright yellow fruiting bodies
formed after approximately one week at 30 °C. Agar plugs were transferred to six 1 L
fermentations of MD1 media augmented with 20 mL of XAD-16 resin and 2.0 g baker’s
yeast (pH= 6.8). Fermentation proceeded at 30 °C with orbital shaking at 120 rpm. After two
weeks, the resin and fruiting bodies were filtered away from the broth and first extracted
with 500 mL of methanol and then 500 mL of acetone. The extracts were combined and
concentrated in vacuo. The residue was subjected to a modified Kupchan extraction scheme,
as often employed in our previous works.63 The culture broth was extracted using the
following partition scheme involving hexanes (sample coded FH 82.4 mg), methanol,
(sample coded FM, 239.9 mg) and dichloromethane (sample coded FD, 375.4 mg). A
separate 1 L liquid culture was prepared according to the above protocol and following two
weeks of incubation the resin and fruiting bodies were filtered away. The broth was
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extracted with hexanes, methanol and dichloromethane yielding the following extract: FH,
21.3 mg, FM, 191.2 mg and FD, 279.9 mg.
LC-MS/ELSD Library Fraction Collection and Scale Up Isolation
A [15.0 mg/150 μL] sample of the dichloromethane extract (sample coded DSM 15898 FD)
was used to prepare a standard LC-MS/ELSD library for bioassay evaluation using methods
reported previously.19 Gradient conditions involved using H2O:CH3CN (with 0.1% formic
acid) consisting of 10:90 → 100% over 30 minutes. A duplicate library was then made
using a 12-channel pipette, creating an exact copy and counter balance for analytical
reference and centrifugal drying. Plates were dried and concentrated using a Savant
AES2010 SpeedVac.
Bengamide E (8) was obtained by a 1 L grow up procedure shown in Scheme S1. From the
FM fraction, 34 mg was subjected to HPLC with the elution subsequently split (1:1)
between a S.E.D.E.R.E. model 55 evaporative light scattering detector (ELSD), and a Gilson
215 liquid handler controlled with Gilson Unipoint LC software. The sample was purified
using a Phenomenex Luna (5° C18 150 × 4.60 mm employing a gradient 5:95% → 40%
CH3CN:H2O (40 min) with buffered conditions using NH4OAc, pH 8.8, Et3N to generate
H24 bengamide E (8, 2.2 mg) (Rt = 24.5 min) with spectroscopic data identical to that
reported in the literature and ESI-TOF-HRMS [M+Na]+ = C17H30N2O6Na, calcd.,
381.19961, found, 381.20105 (Error = 3.78232 ppm).
Preparative (P) scale up HPLC isolation of bengamide E’ (13) from the crude extract DSM
15898 FD (375.4 mg) involved 7 injections of a [50 mg/500 μL] solution using a
Phenomenex Synergi (250 × 21.2 mm, 10 micron) column at a flow rate of 10 mL/min.
using solvent conditions of 10:90 → 100% CH3CN:H20 (30 min) to generate five P
fractions. Fraction P2 (167.2 mg) was subjected to repeated reverse phase HPLC using a
Luna 5 μ, C18(2) 100Å 10 × 250 mm column (Phenomenex, Inc., Torrance, CA) in
conjunction with a guard column using a larger 10.0 × 10.0 mm C18 (ODS) cartridge
(Holder part number: AJ0-7220, Cartridge part number: AJ0-7221) using the solvent
conditions above. The fractions were monitored with a S.E.D.E.R.E. model 55 evaporative
light scattering detector (ELSD) to generate a pure product P2H4 containing bengamide E’
(13, 31.8 mg). Fraction P2H5 (4.4 mg) was further purified using a reversed-phase 150 ×
4.60 mm 5 μm C18 Phenomenex Luna column with a gradient of 5:95% → 40%
CH3CN:H2O (40 min) with buffered conditions using NH4OAc, pH 8.8, Et3N to generate
P2H5H2 bengamide F’ (14, 1.4 mg).
NF-κB luciferase and Human colon tumor (HCT) 116 assay
Extracts and pure compounds were tested in an NF-κB luciferase reporter assay in mouse
macrophage (RAW264.7) immune cells to determine NF-κB activity. The RAW 264.7 cells
were plated as 5 × 104 cells per well plate. Stably transfected RAW264.7 cells with the NF-
κB reporter gene were plated in 96-well plates. Following a 24 h recovery period, the cells
were treated with the extract(s) or compound(s) for an additional 18 h in the presence of
LPS (100 ng/mL). To check NF-κB -luciferase activity, the Luciferase Reporter Assay
System purchased from Promega (Madison, WI) were used. Cell lysates (15 μL) from
treated RAW264.7 cells were placed in opaque 96 well plates. Luciferase Assay Reagent (50
μL) was injected and read by a fluorometer (LMAX 2, Molecular devices). The values
(IC50) represent the mean ± SE for n = 3. The IC50 values reported against HCT cell lines
were obtained using methods described previously.64
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Determination of phosphorylation of IkBα by Western blot analysis
RAW264.7 cells were cultured in 6-well plates to near confluency, treated with increasing
concentrations of compounds in the presence of LPS and incubated at 37°C for 4 hr. Cells
were immediately harvested in 200 μL of loading buffer (10% glycerol, 5% 2-
mercaptoethanol, 10% SDS, 0.125 M Tris–HCl pH 6.7, 0.15% bromophenol blue),
sonicated for 15 s, heated to 99.9 °C for 5 min and fractionated by electrophoresis on 4–15%
polyacrylamide, 0.1% SDS resolving gels (BioRad). Proteins were electrically transferred to
Immobilon-II membranes (Millipore, Billerica, MA), and blocked at room temperature for 1
h with 5% non-fat dry milk in wash buffer (10 mM Tris–HCl, pH 8.0, 150 mM NaCl, 0.05%
Tween 20). Blots were subsequently incubated with antibodies against mouse phosphor-IκB
and IκB (Cell Signaling, 1:1000). Immunoreactive proteins were detected after 1 h of
incubation at room temperature with appropriate horseradish peroxidase-conjugated
secondary antibodies (Santa Cruz Biotechnology, 1:3000 dilution). Blots were incubated
with Western Lighting Chemiluminecense Reagent Plus (PerkinElmer Life Sciences) and
chemiluminescence was detected using CL-X Posure Clear Blue X-ray Film (Thermo
Scientific).
Griess (Nitrite Oxide) Assay
Murine macrophage cells (RAW264.7) were plated in a 96-well plate in RPMI1640 and
incubated at 37°C for 24 h. The medium was changed, allowing cell induction by addition of
compound and lipopolysaccharide (LPS) from Escherichia coli 055:B5 (LPS; Sigma-
Aldrich) in the medium. After incubation, 50 μl of the supernatant was removed and
incubated with the Griess reagent [150 μl; 0.5% sulfanilamide, 0.05% (N-1-naphthyl)
ethylenediamine dihydrochloride, 2.5% H3PO4 and 97% H2O by weight] for 30 min at
room temperature in the dark. The absorbance is measured at 530 nm on a Dynex MRX II
microplate spectrophotometer and calibrated using a standard curve constructed with sodium
nitrite to yield NO2− concentration.
in vitro Quantitative real-time PCR analysis
The bengamides A (6) and B (7) were evaluated in triplicate (n = 3) for their effects on
nitrous oxide (NO) production (n = 3), TNFα (n = 3), IL-6 (n = 3) and MCP1 (n = 3). The
results are presented as means ± standard deviation of the mean (STD). Differences in mean
values between groups were analyzed by a one-way analysis of variance (ANOVA) using
GraphPad Prism software (version 3.02 for Windows, GraphPad Software Inc., La Jolla,
CA, USA). The statistical significance of mean differences was based on a p value of <0.05.
A total RNA of 0.5 μg from RAW264.7 cells after treatment was exposed to DNase I
treatment (Amersham Biosciences). cDNA was synthesised from DNase-treated RNA by
reverse transcription. cDNAs from each experimental condition were pooled and PCR array
analysis was performed according to the manufacturer protocol with the RT2 Real-Time™
SYBR Green PCR Master Mix (SuperArray Bioscience Corporation). Quantitative real-time
PCR array was performed on Mx3005P™ QPCR system (Stratagene, La Jolla, CA, USA).
mRNA expression for each gene was normalized using the expression of GAPDH as a
control housekeeping gene.
MTT Cytotoxicity assay
Extract LCMS-UV-ELSD library well fractions were tested at 20 μg/mL respectively based
on assumed weights of 0.15 mg / well estimated from a 15 mg injection divided into two
library plates (7.5 mg each) equally fractionated / 50 wells ~ 0.15 mg/well. Pure compounds
were tested using concentrations reported using a previously reported MTT assay20 in
murine macrophage (RAW264.7) cells to determine cytotoxic activity. Cells in 96-well
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plates in the required growth medium were treated with extracts dissolved in DMSO for 20 h
(RAW264.7). After incubation, MTT solution was added to wells and incubated for another
2h. Media were removed and DMSO was added to dissolve purple precipitates. Then plates
were read at 570 nm using a plate reader.
Bengamide A (6): white powder; LRESITOFMS m/z 581.5 [M-H2O+H]+, 599.5 [M+H]+.
LCMS and 1H NMR data is provided in Figures S13-S14 (in the supporting information)
and is equivalent to spectroscopic data reported previously.38
Bengamide B (7): white powder; LRESITOFMS m/z 607.5 [M+Na]+. LCMS and 1H NMR
data is provided in Figures S15–S16 and is equivalent to spectroscopic data reported
previously.38
Bengamide E (8): yellow oil; LRESITOFMS m/z 341.5 [M-H2O+H]+. LCMS and 1H NMR
data is provided in Figures S2–S3 and is equivalent to spectroscopic data reported
previously.38
Bengamide F (9): clear oil; LRESITOFMS m/z 355.3 [M-H2O+H]+. LCMS and 1H NMR
data is provided in Figures S4–S5 and is equivalent to spectroscopic data reported
previously.38
LAF-389 (12): white powder; LRESITOFMS m/z 499.2 [M+H]+. This compound was
generously provided by Novartis Institute for Biomedical Research. LCMS and 1H NMR
data is provided in Figures S17–S18 and is equivlaeny to sprectroscopic data reported
previously.44
Bengamide E’ (13): white powder; 1H NMR data see Figures S4–10, and Table S1,
Supporting Information; LRESITOFMS m/z 355.3 [M-H2O+H]+. HRESITOFMS [M+H]+ =
C18H33N2O6, found, 373.2340, calc’d., 373.2331 (Error = 0.0009 ppm).
Bengamide F’ (14): white powder; 1H NMR data see Figure S11–12, and Table S2,
Supporting Information; LRESITOFMS m/z 369.3 [M-H2O+H]+. HRMS [M+Na]+ =
C19H34N2O6Na, found, 409.22895, calc’d., 409.23091 (Error = 4.78541 ppm).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Structural similarities between sponge-derived and myxobacteria-derived compounds.
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Observed LC-MS/ELSD peak library trace with selected annotations including: (a) m/z ions
associated with key metabolites, and (b) NF-κB inhibition responses modulated by celastrol
(5) measured in the luciferase assay of M. virescens (extract coded DSM 15898 FD) LC
peak library fractions.
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Comparative 13C NMR chemical shifts of naturally occurring and synthetic bengamide E
(8), diastereotopic mixture of E’ (13) showing parallelisms to justify assignment of the
absolute configurations assigned at C5, C6, C7, C8 for 13.
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Western blot analysis of bengamide A (6), B (7), E (8) and F (9) at varying concentrations
and their suppression of phosphorylation of IκBα with β actin as a control.
Johnson et al. Page 15














Effects of bengamide A (6) and B (7) on the inhibition of lipopolysacharide (LPS) induced
expression of: (a) nitrous oxide (NO), (b) tumor necrosis factor (TNFα), (c) interleukin-6
(IL-6) and (d) monocyte chemotactic protein-1 (MCP-1) as measured by qPCR. *LPS (100
ng/mL) is used as a positive control and added to (0.01–10 μM) samples of 6 and 7. Data are
presented as mean ±SEM of three independent experiments.**p<0.05, ***p<0.001.
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